论文部分内容阅读
目的观察替加环素联合头孢哌酮舒巴坦治疗临床多重或泛耐药鲍曼不动杆菌肺部感染的疗效。方法选择本院2013年5月~2016年6月48例多重或泛耐药鲍曼不动杆菌肺部感染患者,将其分为A组(替加环素联合头孢哌酮舒巴坦组)及B组(碳青霉烯类联合头孢哌酮舒巴坦组),各24例。回顾分析患者治疗前后WBC、CRP、PCT等炎症指标的变化以及细菌清除率、疗效的情况并进行分析。结果两组治疗后炎症指标WBC、CRP和PCT的水平均显著低于治疗前,差异有统计学意义(P<0.05),且A组优于B组。A组细菌清除率及治疗总有效率均显著高于B组,差异有统计学意义(P<0.05)。结论替加环素联合头孢哌酮舒巴坦可以明显减轻多重或泛耐药鲍曼不动杆菌患者的炎性反应,提高细菌清除率和治疗有效率。
Objective To observe the curative effect of tigecycline combined with cefoperazone sulbactam on clinical multidrug or pan-drug resistant Acinetobacter baumannii pulmonary infection. Methods Forty-eight patients with multiple or pan-resistant Acinetobacter baumannii infection in our hospital from May 2013 to June 2016 were divided into group A (tigecycline plus cefoperazone sulbactam group) And group B (carbapenem combined with cefoperazone sulbactam group), each 24 cases. The changes of WBC, CRP, PCT and other inflammatory indexes before and after treatment were analyzed retrospectively, and the bacterial clearance rate and curative effect were analyzed and analyzed. Results The levels of inflammatory markers WBC, CRP and PCT in both groups after treatment were significantly lower than those before treatment (P <0.05), and group A was better than group B. The bacterial clearance rate and the total effective rate of treatment in group A were significantly higher than those in group B, the difference was statistically significant (P <0.05). Conclusion The combination of tigecycline and cefoperazone sulbactam can significantly reduce the inflammatory response of patients with multiple or pan-resistant Acinetobacter baumannii and improve the bacterial clearance rate and treatment efficiency.